Dinaciclib inhibits the stemness of two subtypes of human breast cancer cells by targeting the FoxM1 and Hedgehog signaling pathway

Tsao,Ai-Ni; Chuang,Yu-Syuan; Lin,Yen-Chun; Su,Yeu; Chao,Ta-Chung

doi:10.3892/or.2022.8316

Dinaciclib inhibits the stemness of two subtypes of human breast cancer cells by targeting the FoxM1 and Hedgehog signaling pathway

Authors:
- Ai-Ni Tsao
- Yu-Syuan Chuang
- Yen-Chun Lin
- Yeu Su
- Ta-Chung Chao
View Affiliations

Affiliations: Institute of Biopharmaceutical Sciences, School of Pharmaceutical Sciences, National Yang Ming Chiao Tung University, Taipei 11200, Taiwan, R.O.C., Division of Medical Oncology, Department of Oncology, Taipei Veterans General Hospital, Taipei 11200, Taiwan, R.O.C.
Published online on: April 12, 2022 https://doi.org/10.3892/or.2022.8316
Article Number: 105

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Cyclin‑dependent kinase (CDK)4/6 inhibitors in combination with endocrine therapy are the current standard of care used in the first‑line treatment of hormone receptor‑positive/HER2‑negative metastatic breast cancer (BC). Although CDK4/6 inhibitors mainly target the cell cycle, emerging evidence has indicated further potential roles of CDKs other than regulating cell cycle progression. The G₁ and G₂/M transition regulators, including cyclins D and E, as well as their catalytic partners, CDK2, CDK4 and CDK6, have been reported to play crucial roles in pluripotency maintenance and cell fate decisions of human pluripotent stem cells by controlling transcription factors, signaling pathways and epigenetic regulators. Dinaciclib, a CDK1/2/5/9 inhibitor, is currently being evaluated in clinical trials against various cancer types, including BC. However, the underlying molecular mechanisms of CDK1/2/5/9 inhibitors in regulating BC stemness remain poorly understood. The present study aimed to examine the stemness‑inhibitory effects of dinaciclib in MCF‑7 (luminal) and HCC‑1806 (triple‑negative) BC cells. We found that this drug not only effectively reduced the self‑renewal abilities and other malignant properties, but also dose‑dependently decreased the protein expression levels of three BC stem cell markers, CD44, aldehyde dehydrogenase 1 family member A1 (ALDH1A1) and BMI1 proto‑oncogene, polycomb ring finger (Bmi1), as well as three embryonic stem cell markers, Oct4, Nanog and Sox2. Moreover, the dinaciclib‑induced decrease of Oct4 and Nanog protein expression was able to be restored by co‑treatment with MG‑132, a proteasome inhibitor. Forkhead box M1 (FoxM1), both a stemness‑stimulating transcription factor and a cell cycle regulator, along with the Hedgehog signaling pathway, were identified as the therapeutic targets of dinaciclib. Collectively, the present results demonstrated a novel role of dinaciclib in suppressing BC stemness and indicated its potential use for future cancer treatments.

View Figures

View References

1	Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
2	Ghoncheh M, Pournamdar Z and Salehiniya H: Incidence and mortality and epidemiology of breast cancer in the world. Asian Pac J Cancer Prev. 17:43–46. 2016. View Article : Google Scholar : PubMed/NCBI
3	Nguyen PL, Taghian AG, Katz MS, Niemierko A, Abi Raad RF, Boon WL, Bellon JR, Wong JS, Smith BL and Harris JR: Breast cancer subtype approximated by estrogen receptor, progesterone receptor, and HER-2 is associated with local and distant recurrence after breast-conserving therapy. J Clin Oncol. 26:2373–2378. 2008. View Article : Google Scholar : PubMed/NCBI
4	Sotiriou C and Pusztai L: Gene-expression signatures in breast cancer. N Engl J Med. 360:790–800. 2009. View Article : Google Scholar : PubMed/NCBI
5	André F and Zielinski CC: Optimal strategies for the treatment of metastatic triple-negative breast cancer with currently approved agents. Ann Oncol. 23 (Suppl 6):vi46–vi51. 2012. View Article : Google Scholar : PubMed/NCBI
6	Perou CM, Sørlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, et al: Molecular portraits of human breast tumours. Nature. 406:747–752. 2000. View Article : Google Scholar : PubMed/NCBI
7	Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ and Clarke MF: Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA. 100:3983–3988. 2003. View Article : Google Scholar : PubMed/NCBI
8	Malumbres M and Barbacid M: Cell cycle, Cdks and cancer: A changing paradigm. Nat Rev Cancer. 9:153–166. 2009. View Article : Google Scholar : PubMed/NCBI
9	Plaks V, Kong N and Werb Z: The cancer stem cell niche: How essential is the niche in regulating stemness of tumor cells? Cell Stem Cell. 16:225–238. 2015. View Article : Google Scholar : PubMed/NCBI
10	Pavlopoulou A, Oktay Y, Vougas K, Louka M, Vorgias CE and Georgakilas AG: Determinants of resistance to chemotherapy and ionizing radiation in breast cancer stem cells. Cancer Lett. 380:485–493. 2016. View Article : Google Scholar : PubMed/NCBI
11	Evans T, Rosenthal ET, Youngblom J, Distel D and Hunt T: Cyclin: A protein specified by maternal mRNA in sea urchin eggs that is destroyed at each cleavage division. Cell. 33:389–396. 1983. View Article : Google Scholar : PubMed/NCBI
12	Suryadinata R, Sadowski M and Sarcevic B: Control of cell cycle progression by phosphorylation of cyclin-dependent kinase (CDK) substrates. Biosci Rep. 30:243–255. 2010. View Article : Google Scholar : PubMed/NCBI
13	Nurse P and Thuriaux P: Regulatory genes controlling mitosis in the fission yeast Schizosaccharomyces pombe. Genetics. 96:627–637. 1980. View Article : Google Scholar : PubMed/NCBI
14	Lim S and Kaldis P: Cdks, cyclins and CKIs: Roles beyond cell cycle regulation. Development. 140:3079–3093. 2013. View Article : Google Scholar : PubMed/NCBI
15	Song X, Kenston SSF, Zhao J, Yang D and Gu Y: Roles of FoxM1 in cell regulation and breast cancer targeting therapy. Med Oncol. 34:412017. View Article : Google Scholar : PubMed/NCBI
16	Lange C and Calegari F: Cdks and cyclins link G1 length and differentiation of embryonic, neural and hematopoietic stem cells. Cell Cycle. 9:1893–1900. 2010. View Article : Google Scholar : PubMed/NCBI
17	Neganova I, Tilgner K, Buskin A, Paraskevopoulou I, Atkinson SP, Peberdy D, Passos JF and Lako M: CDK1 plays an important role in the maintenance of pluripotency and genomic stability in human pluripotent stem cells. Cell Death Dis. 5:e15082014. View Article : Google Scholar : PubMed/NCBI
18	Opyrchal M, Salisbury JL, Iankov I, Goetz MP, McCubrey J, Gambino MW, Malatino L, Puccia G, Ingle JN, Galanis E and D'Assoro AB: Inhibition of Cdk2 kinase activity selectively targets the CD44⁺/CD24⁻/low stem-like subpopulation and restores chemosensitivity of SUM149PT triple-negative breast cancer cells. Int J Oncol. 45:1193–1199. 2014. View Article : Google Scholar : PubMed/NCBI
19	Sun LH, Ban T, Liu CD, Chen QX, Wang X, Yan ML, Hu XL, Su XL, Bao YN, Sun LL, et al: Activation of Cdk5/p25 and tau phosphorylation following chronic brain hypoperfusion in rats involves microRNA-195 down-regulation. J Neurochem. 134:1139–1151. 2015. View Article : Google Scholar : PubMed/NCBI
20	De Falco G and Giordano A: CDK9: From basal transcription to cancer and AIDS. Cancer Biol Ther. 1:342–347. 2002. View Article : Google Scholar : PubMed/NCBI
21	Hatch VL, Marin-Barba M, Moxon S, Ford CT, Ward NJ, Tomlinson ML, Desanlis I, Hendry AE, Hontelez S, van Kruijsbergen I, et al: The positive transcriptional elongation factor (P-TEFb) is required for neural crest specification. Dev Biol. 416:361–372. 2016. View Article : Google Scholar : PubMed/NCBI
22	Cortés N, Guzmán-Martínez L, Andrade V, González A and Maccioni RB: CDK5: A unique CDK and its multiple roles in the nervous system. J Alzheimers Dis. 68:843–855. 2019. View Article : Google Scholar : PubMed/NCBI
23	Hanahan D and Weinberg RA: The hallmarks of cancer. Cell. 1:57–70. 2000. View Article : Google Scholar : PubMed/NCBI
24	Turner NC, Slamon DJ, Ro J, Bondarenko I, Im SA, Masuda N, Colleoni M, DeMichele A, Loi S, Verma S, et al: Overall survival with palbociclib and fulvestrant in advanced breast cancer. N Engl J Med. 379:1926–1936. 2018. View Article : Google Scholar : PubMed/NCBI
25	Im SA, Lu YS, Bardia A, Harbeck N, Colleoni M, Franke F, Chow L, Sohn J, Lee KS, Campos-Gomez S, et al: Overall survival with ribociclib plus endocrine therapy in breast cancer. N Engl J Med. 381:307–316. 2019. View Article : Google Scholar : PubMed/NCBI
26	Goetz MP, Toi M, Campone M, Sohn J, Paluch-Shimon S, Huober J, Park IH, Trédan O, Chen SC, Manso L, et al: MONARCH 3: Abemaciclib as initial therapy for advanced breast cancer. J Clin Oncol. 35:3638–3646. 2017. View Article : Google Scholar : PubMed/NCBI
27	Portman N, Alexandrou S, Carson E, Wang S, Lim E and Caldon CE: Overcoming CDK4/6 inhibitor resistance in ER-positive breast cancer. Endocr Relat Cancer. 26:R15–R30. 2018. View Article : Google Scholar : PubMed/NCBI
28	Chen L, Yang G and Dong H: Everolimus reverses palbociclib resistance in ER+ human breast cancer cells by inhibiting phosphatidylinositol 3-kinase(PI3K)/Akt/mammalian target of rapamycin (mTOR) pathway. Med Sci Monit. 25:77–86. 2019. View Article : Google Scholar : PubMed/NCBI
29	Kettner NM, Vijayaraghavan S, Durak MG, Bui T, Kohansal M, Ha MJ, Liu B, Rao X, Wang J, Yi M, et al: Combined Inhibition of STAT3 and DNA repair in palbociclib-resistant ER-positive breast cancer. Clin Cancer Res. 25:3996–4013. 2019. View Article : Google Scholar : PubMed/NCBI
30	Chien AJ, Rahmaputri S, Dittrich HF, Majure MC, Rugo HS, Melisko ME and Goga A: A phase Ib trial of the cyclin-dependent kinase inhibitor dinaciclib (dina) in combination with pembrolizumab (P) in patients with advanced triple-negative breast cancer (TNBC). J Clin Oncol. 37 (Suppl 15):S10722019. View Article : Google Scholar
31	Rajput S, Khera N, Guo Z, Hoog J, Li S and Ma CX: Inhibition of cyclin dependent kinase 9 by dinaciclib suppresses cyclin B1 expression and tumor growth in triple negative breast cancer. Oncotarget. 7:56864–56875. 2016. View Article : Google Scholar : PubMed/NCBI
32	Kang J, Sergio CM, Sutherland RL and Musgrove EA: Targeting cyclin-dependent kinase 1 (CDK1) but not CDK4/6 or CDK2 is selectively lethal to MYC-dependent human breast cancer cells. BMC Cancer. 14:322014. View Article : Google Scholar : PubMed/NCBI
33	Tay Y, Zhang J, Thomson AM, Lim B and Rigoutsos I: MicroRNAs to Nanog, Oct4 and Sox2 coding regions modulate embryonic stem cell differentiation. Nature. 455:1124–1128. 2008. View Article : Google Scholar : PubMed/NCBI
34	Liu L, Michowski W, Inuzuka H, Shimizu K, Nihira NT, Chick JM, Li N, Geng Y, Meng AY, Ordureau A, et al: G1 cyclins link proliferation, pluripotency and differentiation of embryonic stem cells. Nat Cell Biol. 19:177–188. 2017. View Article : Google Scholar : PubMed/NCBI
35	Anders L, Ke N, Hydbring P, Choi YJ, Widlund HR, Chick JM, Zhai H, Vidal M, Gygi SP, Braun P and Sicinski P: A systematic screen for CDK4/6 substrates links FOXM1 phosphorylation to senescence suppression in cancer cells. Cancer Cell. 20:620–634. 2011. View Article : Google Scholar : PubMed/NCBI
36	Wierstra I: Cyclin D1/Cdk4 increases the transcriptional activity of FOXM1c without phosphorylating FOXM1c. Biochem Biophys Res Commun. 431:753–759. 2013. View Article : Google Scholar : PubMed/NCBI
37	Xue J, Zhou A, Tan C, Wu Y, Lee HT, Li W, Xie K and Huang S: Forkhead box M1 is essential for nuclear localization of glioma-associated oncogene homolog 1 in glioblastoma multiforme cells by promoting importin-7 expression. J Biol Chem. 290:18662–18670. 2015. View Article : Google Scholar : PubMed/NCBI
38	Zhang N, Wei P, Gong A, Chiu WT, Lee HT, Colman H, Huang H, Xue J, Liu M, Wang Y, et al: FoxM1 promotes β-catenin nuclear localization and controls Wnt target-gene expression and glioma tumorigenesis. Cancer Cell. 20:427–442. 2011. View Article : Google Scholar : PubMed/NCBI
39	Elango R, Vishnubalaji R, Manikandan M, Binhamdan SI, Siyal AA, Alshawakir YA, Alfayez M, Aldahmash A and Alajez NM: Concurrent targeting of BMI1 and CDK4/6 abrogates tumor growth in vitro and in vivo. Sci Rep. 9:136962019. View Article : Google Scholar : PubMed/NCBI
40	Ghia P, Scarfò L, Perez S, Pathiraja K, Derosier M, Small K, McCrary Sisk C and Patton N: Efficacy and safety of dinaciclib vs ofatumumab in patients with relapsed/refractory chronic lymphocytic leukemia. Blood. 129:1876–1878. 2017. View Article : Google Scholar : PubMed/NCBI
41	Gregory G, Walker P, Mahadevan D, Wang D, Chang J, Hernandez-Ilizaliturri F, Klein A, Rybka W, Wagner-Johnston N, Escobar C, et al: Antitumor activity of pembrolizumab plus dinaciclib in patients with diffuse large b cell lymphoma: The phase 1b keynote-155 study. Hematol Oncol. 37:328–329. 2019. View Article : Google Scholar
42	Ravindran Menon D, Luo Y, Arcaroli JJ, Liu S, KrishnanKutty LN, Osborne DG, Li Y, Samson JM, Bagby S, Tan AC, et al: CDK1 interacts with Sox2 and promotes tumor initiation in human melanoma. Cancer Res. 78:6561–6574. 2018. View Article : Google Scholar : PubMed/NCBI
43	Wang J, Huang Y, Cai J, Ke Q, Xiao J, Huang W, Li H, Qiu Y, Wang Y, Zhang B, et al: A nestin-cyclin-dependent kinase 5-dynamin-related protein 1 axis regulates neural stem/progenitor cell stemness via a metabolic shift. Stem Cells. 36:589–601. 2018. View Article : Google Scholar : PubMed/NCBI
44	Xie Q, Wu Q, Kim L, Miller TE, Liau BB, Mack SC, Yang K, Factor DC, Fang X, Huang Z, et al: RBPJ maintains brain tumor-initiating cells through CDK9-mediated transcriptional elongation. J Clin Invest. 126:2757–2772. 2016. View Article : Google Scholar : PubMed/NCBI
45	Moretto-Zita M, Jin H, Shen Z, Zhao T, Briggs SP and Xu Y: Phosphorylation stabilizes Nanog by promoting its interaction with Pin1. Proc Natl Acad Sci USA. 107:13312–13317. 2010. View Article : Google Scholar : PubMed/NCBI
46	Nishi M, Akutsu H, Masui S, Kondo A, Nagashima Y, Kimura H, Perrem K, Shigeri Y, Toyoda M, Okayama A, et al: A distinct role for Pin1 in the induction and maintenance of pluripotency. J Biol Chem. 286:11593–11603. 2011. View Article : Google Scholar : PubMed/NCBI
47	Yang N, Wang C, Wang Z, Zona S, Lin SX, Wang X, Yan M, Zheng FM, Li SS, Xu B, et al: FOXM1 recruits nuclear Aurora kinase A to participate in a positive feedback loop essential for the self-renewal of breast cancer stem cells. Oncogene. 36:3428–3440. 2017. View Article : Google Scholar : PubMed/NCBI
48	Ring A, Nguyen C, Smbatyan G, Tripathy D, Yu M, Press M, Kahn M and Lang JE: CBP/β-catenin/FOXM1 is a novel therapeutic target in triple negative breast cancer. Cancers (Basel). 10:5252018. View Article : Google Scholar : PubMed/NCBI
49	Besharat ZM, Abballe L, Cicconardi F, Bhutkar A, Grassi L, Le Pera L, Moretti M, Chinappi M, D'Andrea D, Mastronuzzi A, et al: Foxm1 controls a pro-stemness microRNA network in neural stem cells. Sci Rep. 8:35232018. View Article : Google Scholar : PubMed/NCBI
50	Teh MT, Wong ST, Neill GW, Ghali LR, Philpott MP and Quinn AG: FOXM1 is a downstream target of Gli1 in basal cell carcinomas. Cancer Res. 62:4773–4780. 2002.PubMed/NCBI
51	Wang D, Hu G, Du Y, Zhang C, Lu Q, Lv N and Luo S: Aberrant activation of hedgehog signaling promotes cell proliferation via the transcriptional activation of forkhead box M1 in colorectal cancer cells. J Exp Clin Cancer Res. 36:232017. View Article : Google Scholar : PubMed/NCBI
52	Kalathil D, John S and Nair AS: FOXM1 and cancer: Faulty cellular signaling derails homeostasis. Front Oncol. 10:6268362021. View Article : Google Scholar : PubMed/NCBI